The Evolving Standard of Care in AML: FLT3 Inhibitors
Please complete Pre-test
Chapter 1 of 2
Release Date: October 16, 2018
Expiration Date: October 16, 2019
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
New therapies are helping to improve survival in patients with AML who present with FLT3 mutations. In this activity, Dr. Perl reviews the current status and future direction of first- and second-generation FLT3 inhibitors, both approved and in clinical trials.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Summarize the diagnosis and prognosis of FLT3-mutated AML, and the role of FLT3 inhibitors in the treatment of patients with this mutation
- Outline the efficacy and safety of current and emerging FLT3 inhibitors for the treatment of AML
- Incorporate individual patient and treatment-related factors into the decision-making process for patients with AML
The Evolving Standard of Care in AML: FLT3 Inhibitors - Alexander Perl, MD
Instructions for Participation and Credit
This activity is eligible for credit through October 16, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Alexander Perl, MD
Associate Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Dr. Alexander Perl is a member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania, where he is an Associate Professor of Medicine. His particular expertise is in FLT3 inhibition as a therapeutic strategy for acute myeloid leukemia, clinical trials, and mechanisms of resistance to tyrosine kinase inhibitors.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-034-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Alexander Perl has received honoraria as a consultant from Arog Pharmaceuticals, Inc., Asana BioSciences, LLC., Astellas Pharma US, Inc., Daiichi Sankyo, Inc., Novartis AG, and NewLink Genetics Corporation.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.